FDA nod for Pfizer’s combination therapy for non-small cell cancer
HQ Team October 12, 2023: The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer. The FDA.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team October 12, 2023: The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer. The FDA.
HQ Team October 4, 2023: The US Food and Drug Administration has cleared Novavax’s updated Covid-19 vaccine for emergency use in adolescents 12.
HQ Team September 29, 2023: Pfizer announced the availability of its migraine management drug Rimegepant in Hong Kong — the company’s first market.
HQ Team September 13, 2023: The US national public agency has recommended a COVID-19 vaccination policy where updated shots are given starting from.
HQ Team September 12, 2023: The US drug and medicine regulator, the FDA, approved COVID-19 vaccines made by Moderna Inc., Pfizer Inc., and BioNTech.
HQ Team August 22, 2023: Pfizer Inc’s Abrysvo, a vaccine used in pregnant women to prevent lower respiratory tract infection caused by respiratory.
HQ Team August 15, 2023: The USFDA has granted accelerated approval for Pfizer Inc’s Elrexfio to treat incurable blood cancer, multiple myeloma, that.
HQ Team July 29, 2023: Alexion, AstraZeneca Rare Disease, an arm of AstraZeneca group, has signed a $1 billion pact with Pfizer for.
HQ Team July 24, 2023: British pharmaceutical firm, GSK Plc., has got marketing authorization from the European Medicines Authority for its injectable, and.
HQ Team July 4, 2023: Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, has inked two deals worth $897 million.